Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test.
OBJECTIVE
To compare the levels of interleukin (IL)-1beta, IL-6, and matrix metalloproteinase (MMP)-8 in the vaginal secretions of pregnant women with a positive fetal fibronectin (fFN) test result with or without asymptomatic bacterial vaginosis (BV) before and after treatment with oral clindamycin.


METHODS
A prospective cohort study was conducted among 43 pregnant women with a positive fFN test result. All patients were treated with clindamycin, and the pre- and post-treatment levels of IL-1beta, IL-6, and MMP-8 were compared.


RESULTS
Before treatment, levels of IL-1beta and MMP-8 were significantly higher in women with BV compared with women without BV (P<0.05). Vaginal levels of IL-1beta and IL-6, but not MMP-8, decreased after treatment in pregnant women with BV.


CONCLUSIONS
The inability of clindamycin to decrease MMP-8 vaginal levels may explain why it is ineffective in reducing preterm birth in pregnant women with positive fFN and BV.
Diaz-Cueto
Laura
L
Research Unit in Reproductive Medicine, Luis Castelazo Ayala Gynecology and Obstetrics Hospital, IMSS, Mexico City, Mexico.
Dominguez-Lopez
Pablo
P
Tena-Alavez
Gilberto
G
Cuica-Flores
Adrian
A
Rosales-Ortiz
Sergio
S
Arechavaleta-Velasco
Fabian
F
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology* / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D053583:Interleukin-1beta / Q000187:drug effects / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D020784:Matrix Metalloproteinase 8 / Q000187:drug effects* / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000503:physiopathology; D047928:Premature Birth / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D014621:Vagina / Q000378:metabolism / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
D000900:Anti-Bacterial Agents; C403421:FFN protein, human; D005353:Fibronectins; D053583:Interleukin-1beta; D015850:Interleukin-6; D002981:Clindamycin; D020784:Matrix Metalloproteinase 8